A phase I clinical study of eFT226 in B cell malignancies

Trial Profile

A phase I clinical study of eFT226 in B cell malignancies

Planning
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs EFT-226 (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Dec 2017 New trial record
    • 11 Dec 2017 According to an Effector Therapeutics media release, the company intends to initiate this study in the firs half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top